Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911269 | 0.81 | TSHR (0.37) | TSHRALDH1A1CA1CA2CA12 | |
| SCHEMBL2715609 | 0.75 | CA1 (0.48) | CA1CA2CA9CA12CA14 | |
| SCHEMBL17672729 | 0.73 | CA1 (0.36) | CA1CA2CA12CA14 | |
| SCHEMBL24317683 | 0.72 | JAK2 (0.32) | — | |
| SCHEMBL28576757 | 0.71 | ATM (0.33) | — | |
| Hydrochloric Acid SCHEMBL25385328 | 0.70 | JAK2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL25385331 | 0.70 | JAK2 (0.31) | — | |
| SCHEMBL16090593 | 0.70 | MEN1 (0.42) | ALDH1A1CA1CA2CA9CA12 | |
| SCHEMBL14218683 | 0.69 | DNM1 (0.48) | TSHRCA1 | |
| SCHEMBL15833680 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279003-A1 | JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF | Galderma Holding SA (CH) | 2023-09-07 | — | — | US | disclosed |
| WO-2022054006-A1 | NOVEL JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF | Galderma Holding SA (CH) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279003-A1 | JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF | JAK1, JAK2, JAK3 | TSHR 2908/4885ALDH1A1 2676/4885CA1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.